이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ovid Therapeutics 배당금

배당금 기준 확인 0/6

Ovid Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.9%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.42
배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 09

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Nov 10

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Jun 27

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Mar 13

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Sep 09

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

Aug 09

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Jun 09

Ovid Therapeutics: Good Entry Point For Investors

Jun 18

Ovid Therapeutics appoints Jeff Rona as CFO

Jun 04

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Apr 16

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Mar 20

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Mar 18

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Mar 01

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Jan 25

Revisiting Ovid Therapeutics

Jan 14

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Dec 21

Ovid Therapeutics misses goal in Angelman syndrome treatment

Dec 01

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 OVID 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: OVID 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Ovid Therapeutics 시장 대비 배당 수익률

OVID 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (OVID)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Biotechs)	1.9%
애널리스트 예측 (OVID) (최대 3년)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 OVID 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 OVID 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 OVID 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: OVID 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Ovid Therapeutics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

High number of new and inexperienced directors

Ovid Therapeutics Appoints Dr. Amanda Banks, as Chief Development Officer

Ovid Therapeutics Inc. Expands Scientific Advisory Board

Ovid Therapeutics Inc. Announces That eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Small Cap Comp Value Index

Ovid Therapeutics Inc. and Graviton Bioscience Corporation Announce Topline Data from A Phase 1 Clinical Trial Studying OV888/GV101 Capsule

Consensus revenue estimates decrease by 87%, EPS upgraded

Consensus revenue estimates fall by 80%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ovid Therapeutics Inc., Annual General Meeting, Jun 06, 2024

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

President recently bought US$50k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus revenue estimates increase by 1,902%

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Consensus revenue estimates increase by 48%

Ovid Therapeutics Inc. Announces Changes to Its Board

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Consensus revenue estimates increase by 14%

Price target increased by 7.1% to US$5.00

Consensus revenue estimates increase by 60%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Ovid Therapeutics Doses Healthy Volunteers with OV329 in Phase 1 Trial

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2021)

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.23 loss in 2Q 2021)

Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04

We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully

Price target decreased to US$4.70

Ovid Therapeutics Inc., Annual General Meeting, Jun 09, 2022

Price target increased to US$5.50

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to US$5.50

President & Chief Medical Officer notifies of intention to sell stock

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell 3000E Index

Treasurer & Corporate Controller Timothy Daly has left the company

Ovid Therapeutics: Good Entry Point For Investors

Ovid Therapeutics appoints Jeff Rona as CFO

Price target decreased to US$4.88

Investor sentiment improved over the past week

Price target decreased to US$5.40

Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability

Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts

Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates

Takeda Pharmaceutical Company Limited and Ovid Therapeutics Inc. to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

New 90-day high: US$4.04

We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?

Revisiting Ovid Therapeutics

New 90-day low: US$2.42

Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?

Analysts increase revenue estimates to US$11.1m

Ovid Therapeutics Inc. Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

Ovid Therapeutics misses goal in Angelman syndrome treatment

New 90-day high: US$6.84

Price target raised to US$14.67

Revenue beats expectations, earnings disappoint

New 90-day low: US$5.34

Ovid Therapeutics Inc. Announces Results from the Arcade and Endymion Studies of Soticlestat (Ov935/Tak-935) in Patients with Developmental and Epileptic Encephalopathies (Dees), or Rare Epilepsies

Ovid Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

New 90-day high - US$8.00

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Microcap Value Index

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금